Maze Therapeutics, Inc. (MAZE) — 10-K Filings
All 10-K filings from Maze Therapeutics, Inc.. Browse 2 Annual Report reports with AI-powered summaries and risk analysis.
10-K Filings (2)
-
Maze Therapeutics' Lead Drug Shows Promise in Kidney Disease Trial
— Mar 25, 2026 Risk: high
Maze Therapeutics, Inc. (MAZE) is a clinical-stage biopharmaceutical company focused on kidney and metabolic diseases. For the fiscal year ended December 31, 20 - 10-K Filing — Mar 31, 2025
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX